Quinine 200 mg Film-Coated Tablets (DCP Start)

The company has started the Decentralized Procedure (DCP) for Quinine 200 mg Film-Coated Tablets, marking a new step in the expansion of its European generic portfolio.

Building on decades of experience in bringing high-quality, value-oriented pharmaceutical solutions to market, WELDING is pursuing this application in line with its structured and reliable approach to development and registration pathways, aiming to enable timely market access once the procedure is successfully completed.

This step underlines the company’s commitment to reliable, responsible, and sustainable partnership models across the pharmaceutical value chain, and to improving patient access to essential medicines also for niche products. It further expands the company’s Finished Dosage Form (FDF) portfolio. WELDING PHARMA FDF supports partners with value-oriented solutions ranging from development and market access support to long-term supply concepts.

“With the start of this procedure, we continue to strengthen our role as a reliable partner for the pharmaceutical industry,” said Lars Hallmayer, Managing Director, WELDING GmbH & Co. KG. “We thank all teams and partners involved for their expertise and dedication in reaching this milestone, and remain committed to transparent collaboration and long-term responsible business practices.”

The company views this initiative as part of its broader strategy to create sustainable economic value through trusted partnerships and international market expertise. With decades of experience in the pharmaceutical sector and a strong global network, WELDING PHARMA FDF works closely with partners to develop and implement tailored product and licensing solutions.

Further steps toward market availability will be taken in accordance with applicable national requirements, and updates will follow as the procedure progresses.

For media inquiries and partnership opportunities, please contact: https://weldinhttps://welding.eu/en/contact/contact-form-pharma-fdf/g.eu/…

Über die WELDING GmbH & Co. KG

WELDING GmbH & Co. KG, headquartered in Hamburg, is a family-owned company with over 70 years of international experience. The company specializes in the procurement and distribution of pharmaceutical active ingredients, food additives, and feed additives, as well as the development, approval, licensing, and delivery of generic pharmaceuticals. In this regard, WELDING also offers a comprehensive range of services in the field of quality assurance and regulatory affairs.

Firmenkontakt und Herausgeber der Meldung:

WELDING GmbH & Co. KG
Esplanade 39
20354 Hamburg
Telefon: +49 (40) 35908-0
Telefax: +49 (40) 35908-251
http://www.welding.de

Ansprechpartner:
Christian Pemöller
Head of Marketing & Communications
Telefon: +494035908197
E-Mail: presse@welding.eu
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel